Safety, tolerability and multiple dose pharmacokinetics of an immediate release tablet formulation of F901318 in healthy subjects

Trial Profile

Safety, tolerability and multiple dose pharmacokinetics of an immediate release tablet formulation of F901318 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2017

At a glance

  • Drugs F 901318 (Primary)
  • Indications Aspergillosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 May 2017 New trial record
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top